OtherApr 9, 2026, 05:06 PM
Adial Pharmaceuticals Grants Over 100,000 Restricted Stock Awards and Options to Executives and Directors
AI Summary
Adial Pharmaceuticals' Compensation Committee and Board of Directors approved significant equity awards on April 7, 2026, distributing a total of 100,190 Restricted Stock Awards (RSAs) and options for 9,185 shares of common stock. These awards, granted under the 2017 Equity Incentive Plan, aim to incentivize key management and independent directors. The RSAs and options vest fully on the one-year anniversary of the grant date or upon a Change of Control, aligning leadership's interests with long-term shareholder value.
Key Highlights
- The Compensation Committee and Board approved the grant of 100,190 Restricted Stock Awards (RSAs) and options for 9,185 shares of common stock on April 7, 2026.
- CEO Cary Claiborne received 37,985 RSAs, comprising 28,800 for his CEO role and 9,185 for his Director role.
- CFO Vinay Shah was granted 17,325 RSAs for his role as Chief Financial Officer.
- COO Tony Goodman received 26,510 RSAs, with 17,325 for his COO role and 9,185 for his Director role.
- Independent Directors Kevin Schuyler and Robertson H. Gilliland each received 9,185 RSAs for their service.
- Director Kermit Anderson received options to purchase 9,185 shares of common stock at an exercise price of $1.64 per share.
- All RSAs and options vest in full on the earlier of the one-year anniversary of the grant date or upon a Change of Control, as defined in the 2017 Equity Incentive Plan.
Price Impact
More from ADIL